MECHANISMS OF CELL-CYCLE CHECKPOINTS: AT THE CROSSROADS OF CARCINOGENESIS AND DRUG DISCOVERY*

REFERENCES

• Dikic I., Blaukat A. Protein tyrosine kinase-mediated pathways in G protein-coupled receptor signaling. Cell. Biochem. Biophys. 1999; 30(3)369–387
   PubMedGoogle Scholar
• Gutkind J. S. Cell growth control by G protein-coupled receptors: From signal transduction to signal integration. Oncogene 1998; 17: 1331–1342
   PubMed Web of Science ®Google Scholar
• Aaronson S. A., Tronick S. R. Transforming genes of human malignancies. Carcinogen. Compr. Surveys 1985; 10: 35–49
   PubMedGoogle Scholar
• Kraus M. H., Pierce J. H., Flemming T. P., Robbins K. C., DiFiore P. P., Aaronson S. A. Mechanisms by which genes encoding growth factor receptors contribute to malignant conversion. Ann. NY Acad. Sci. 1988; 551: 320–335
   PubMed Web of Science ®Google Scholar
• Tronick S. R., Aaronson S. A. Oncogenes, growth regulation, and cancer. Messenger Phosphoprotein Res. 1988; 21: 201–214
   PubMedGoogle Scholar
• Ross J. S., Fletcher J. A. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am. J. Clin. Pathol. 1999; 112(1)S53–S67
   PubMed Web of Science ®Google Scholar
• Berns E. M., Foekens J. A., Van Staveren I. L., Van Putten W. L., de Koning H. Y., Portengen H., Klijn J. G. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene 1995; 159(1)11–18
   PubMed Web of Science ®Google Scholar
• Yamamoto T., Taya S., Kaibuchi K. Ras-induced transformation and signaling pathway. J. Biochem. 1999; 126(5)779–803
   Google Scholar
• Kerkhoff E., Rapp U. R. Cell cycle targets of Ras/Raf signalling. Oncogene 1998; 17: 1457–1462
   PubMed Web of Science ®Google Scholar
• Facchini L. M., Penn L. Z. The molecular role of Myc in growth and transformation: Recent discoveries lead to new insights. FASEB J. 1998; 12: 633–651
   PubMed Web of Science ®Google Scholar
• Murakami Y., Sekiya T. Accumulation of genetic alterations and their significance in each primary human cancer and cell line. Mutat. Res. 1998; 400: 421–437
   PubMed Web of Science ®Google Scholar
• Vineis P., Malats N., Porta M., Real F. Human cancer, carcinogenic exposures and mutation spectra. Mutat. Res. 1999; 436: 185–194
   PubMed Web of Science ®Google Scholar
• Li E. E., Heflich R. H., Bucci T. J., Manjanatha M. G., Blaydes B. S., Delclos K. B. Relationships of DNA adduct formation, K-ras activation, mutations and tumorigenic activities of 6-nitrochrysene and its metabolites in the lungs of CD-1 mice. Carcinogenesis 1994; 15: 1377–1385
   PubMed Web of Science ®Google Scholar
• Nagao M., Ushijima T., Wakabayashi K. Dietary carcinogens and mammary carcinogenesis. Cancer 1994; 74: 1063–1069
   PubMed Web of Science ®Google Scholar
• Marcu K. B., Bossone S. A., Patel A. J. Myc function and regulation. Annu. Rev. Biochem. 1992; 61: 809–860
   PubMed Web of Science ®Google Scholar
• Spencer C. A., Groudine M. Control of c-Myc regulation in normal and neoplastic cells. Adv. Cancer Res. 1991; 56: 1–48
   PubMed Web of Science ®Google Scholar
• Land H., Parada J. F., Weinberg R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983; 304: 596–602
   PubMed Web of Science ®Google Scholar
• Lugo T. G., Witte O. N. The BCR–ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Molec. Cell. Biol. 1989; 9: 1263–1270
   PubMed Web of Science ®Google Scholar
• Barone M. V., Coutneidge S. A. Myc but not Fos rescue of PDGF signaling block caused by kinase-inactive Src. Nature 1995; 378: 509–512
   PubMed Web of Science ®Google Scholar
• Leone G., DeGregori J., Sears R., Jakoi L., Nevins L. R. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 1997; 387: 422–426
   PubMed Web of Science ®Google Scholar
• Prendergast G. C., Ziff E. B. Methylation-sensitive sequence-specific DNA binding by the c-myc basic region. Science 1991; 251: 186–189
   PubMed Web of Science ®Google Scholar
• Blackwood E. M., Eisenman R. N. Max: A helix–loop–helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991; 251: 1211–1217
   PubMed Web of Science ®Google Scholar
• Prendergast G. C., Lawe D., Ziff E. B. Association of myn, the murine homolog of max, with c-myc stimulates methylation-sensitive DNA binding and ras cotransformation. Cell 1991; 65: 395–407
   PubMed Web of Science ®Google Scholar
• Campisi J., Gray H. E., Pardee A. B., Dean M., Sonenshein G. E. Cell-cycle control of c-myc but not c-ras expression is lost following chemical transformation. Cell 1984; 36: 241–247
   PubMed Web of Science ®Google Scholar
• Kelly K., Cochran B. H., Stiles C. D., Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 1983; 35: 603–610
   PubMed Web of Science ®Google Scholar
• Moore J. P., Hancock D. C., Littlewood T. D., Evan G. I. A sensitive and quantitative enzyme-linked immunosorbence assay for the c-Myc and n-Myc oncoproteins. Oncogene Res. 1987; 2: 65–80
   PubMedGoogle Scholar
• Miltenberger R. J., Sukow K. A., Farnham P. J. An E-box-mediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants. Molec. Cell. Biol. 1995; 15: 2527–2535
   PubMed Web of Science ®Google Scholar
• Bello-Fernandez C., Packham G., Cleveland J. L. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc. Natl. Acad. Sci. USA 1993; 90: 7804–7808
   PubMed Web of Science ®Google Scholar
• Hibshoosh H., Johnson M., Weinstein I. B. Effects of overexpression of ornithine decarboxylase (ODC) on growth control and oncogene-induced cell transformation. Oncogene 1991; 6: 739–743
   PubMed Web of Science ®Google Scholar
• Moshier J. A., Dosescu J., Skunca M., Luk G. D. Transformation of NIH/3T3 cells by ornithine decarboxylase overexpression. Cancer Res. 1993; 53: 2618–2622
   PubMed Web of Science ®Google Scholar
• Johnson R., Spiegelman B., Hanahan D., Wisdom R. Cellular transformation and malignancy induced by ras require c-jun. Molec. Cell. Biol. 1996; 16(8)4504–4511
   PubMed Web of Science ®Google Scholar
• Ikeda K., Monden T., Tsujie M., Izawa H., Yamamoto H., Ohnishi T., Ohue M., Sekimoto M., Tomita N., Monden M. Cyclin D, CDK4 and p16 expression in colorectal cancer. Nippon Rinsho 1996; 54(4)1054–1059
   PubMedGoogle Scholar
• Donnellan R., Chetty R. Cyclin D1 and human neoplasia. Molec. Pathol. 1998; 51(1)1–7
   PubMedGoogle Scholar
• Resnitzky D., Gossen M., Bujard H., Reed S. I. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Molec. Cell. Biol. 1994; 14: 1669–1679
   PubMed Web of Science ®Google Scholar
• Lew D. J., Dulic V., Reed S. I. Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 1991; 66: 1197–1206
   PubMed Web of Science ®Google Scholar
• Matsushime H., Ewen M. E., Strom D. K., Kato J-Y., Hanks S. K., Roussel M. F., Sherr C. J. Identification and properties of an atypical catalytic subunit (p34 psk.J3 cdk4) for mammalian D type G1 cyclins. Cell 1992; 71: 323–334
   PubMed Web of Science ®Google Scholar
• Motokura T., Bloom T., Kim H. G., Juppner H., Ruderman J. V., Kronenberg H. M., Arnold A. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991; 350: 512–515
   PubMed Web of Science ®Google Scholar
• Xiong Y., Connolly T., Futcher B., Beach D. Human D-type cyclin. Cell 1991; 65: 691–699
   PubMed Web of Science ®Google Scholar
• Matsushime H., Quelle D. E., Shurtleff S. A., Shibuya M., Sherr C. J., Kato J.-Y. D-type cyclin-dependent kinase activity in mammalian cells. Molec. Cell. Biol. 1994; 14: 2066–2076
   PubMed Web of Science ®Google Scholar
• Meyerson M., Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Molec. Cell. Biol. 1994; 14: 2077–2086
   PubMed Web of Science ®Google Scholar
• Solomon M. J., Harper J. W., Shuttleworth J. CAK, the p34cdc2 activating kinase, contains a protein identical or closely related to p40MO15. EMBO J. 1993; 12: 3133–3142
   PubMed Web of Science ®Google Scholar
• Roberts J. M., Koff A., Polyak K., Firpo E., Collins S., Ohtsubo M., Massague J. Cyclins, Cdks, and cyclin kinase inhibitors. Cold Spring Harbor Symp. Quant. Biol. 1994; 59: 31–38
   PubMedGoogle Scholar
• Ohtsubo M., Theodoras A. M., Schumacher J., Roberts J. M., Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Molec. Cell. Biol. 1995; 15: 2612–2624
   PubMed Web of Science ®Google Scholar
• Roussel M. F. Key effectors of signal transduction and G1 progression. Adv. Cancer Res. 1998; 74: 1–24
   PubMed Web of Science ®Google Scholar
• Nevins J. R. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ. 1998; 9: 585–593
   PubMedGoogle Scholar
• Harbour J. W., Luo R. X., Dei Santi A., Postigo A. A., Dean D. C. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98: 859–869
   PubMed Web of Science ®Google Scholar
• Brown V. D., Phillips R. A., Gallie B. L. Cumulative effects of phosphorylation of pRb on regulation of E2F activity. Molec. Cell. Biol. 1999; 19(5)3246–3256
   PubMed Web of Science ®Google Scholar
• Lavia P., Jansen-Dürr P. E2F target genes and cell-cycle checkpoint control. BioEssays 1999; 21: 221–230
   PubMedGoogle Scholar
• Schulze A., Zerfass K., Spitkovsky D., Middendorp S., Berges J., Helin K., Jansen-Durr P., Henglein B. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc. Natl. Acad. Sci. USA 1995; 92(24)11,264–11,268
   Google Scholar
• DeGregori J., Kowalik T., Nevins J. R. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis and G1/S-regulatory genes. Molec. Cell. Biol. 1999; 15(10)5846–5847
   Google Scholar
• Buchkovich K., Duffy L. A., Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 1989; 58: 1097–1106
   PubMed Web of Science ®Google Scholar
• Chen P-L., Scully P., Shew J-Y., Wang J. Y. J., Lee W.-H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 1989; 58: 1193–1198
   PubMed Web of Science ®Google Scholar
• Furukawa Y., DeCaprio J. A., Freeman A., Kanakura Y., Nakamura M., Ernst T. J., Livingston D. M., Griffin J. D. Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells. Proc. Natl. Acad. Sci. USA 1990; 87: 2770–2774
   PubMed Web of Science ®Google Scholar
• Mihara K., Cao X-R., Yen A., Chandler S., Driscoll B., Murphree A. L., T'Ang A., Fung Y-K. T. Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 1989; 246: 1300–1303
   PubMed Web of Science ®Google Scholar
• Mittnacht S., Lees J. A., Desai D., Harlow E., Morgan D. O., Weinberg R. A. Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J. 1994; 13: 118–127
   PubMed Web of Science ®Google Scholar
• Sellers W. R., Kaelin W. G., Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer. J. Clin. Oncol. 1997; 15(11)3301–3312
   PubMed Web of Science ®Google Scholar
• Vaughan T. J., Pascall J. C., Brown K. D. Nucleotide sequence and tissue distribution of mouse transforming growth factor-α. Biochim. Biophys. Acta Gene Struct. Express 1992; 1132: 322–324
   PubMed Web of Science ®Google Scholar
• Kitagawa M., Higashi H., Suzuki-Takahashi I., Segawa K., Hanks S. K., Taya Y., Nishimura S., Okuyama A. Phosphorylation of E2F-1 by cyclin A-cdk2. Oncogene 1995; 10: 229–236
   PubMed Web of Science ®Google Scholar
• Devoto S. H., Mudryj M., Pines J., Hunter T., Nevins J. R. A cyclin A-protein kinase complex possesses sequence-specific DNA binding activity: p33cdk2 is a component of the E2F–cyclin A complex. Cell 1992; 68: 167–176
   PubMed Web of Science ®Google Scholar
• Mudryj M., Devoto S. H., Hiebert S. W., Hunter T., Pines J., Nevins J. R. Cell cycle regulation of the E2F transcription factor involves an interaction with cyclin A. Cell 1991; 65: 1243–1253
   PubMed Web of Science ®Google Scholar
• Yang R., Muller C., Huynh V., Fung Y. K., Yee A. S., Koeffler H. P. Functions of cyclin A1 in the cell cycle and its interactions with transcription factor E2F-1 and the Rb family of proteins. Molec. Cell. Biol. 1999; 19(3)2400–2407
   PubMed Web of Science ®Google Scholar
• Nurse P. Universal control mechanism regulating onset of M-phase. Nature 1990; 344: 503–508
   PubMed Web of Science ®Google Scholar
• Ducommun B., Brambilla P., Felix M.-A., Franza B. R., Karsenti E., Jr., Draetta G. cdc2 phosphorylation is required for its interaction with cyclin. EMBO J. 1991; 10: 3311–3319
   PubMed Web of Science ®Google Scholar
• Gould K. L., Nurse P. Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis. Nature 1989; 342: 39–45
   PubMed Web of Science ®Google Scholar
• Liu F., Stanton J. J., Wu Z., Piwnica-Worms H. The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and golgi complex. Molec. Cell. Biol. 1997; 17: 571–583
   PubMed Web of Science ®Google Scholar
• Lundgren K., Walworth N., Booher R., Dembski M., Kirschner M., Beach D. mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2. Science 1991; 270: 86–90
   Google Scholar
• Mueller P. R., Coleman T. R., Kumagai A., Dunphy A. Myt1: A membrane-associated inhibitory kinase that phosphorylates cdc2 on both threonine-14 and tyrosine-15. Science 1995; 270: 86–93
   PubMed Web of Science ®Google Scholar
• Galaktionov K., Beach D. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: Evidence for multiple roles of mitotic cyclins. Cell 1991; 67: 1181–1194
   PubMed Web of Science ®Google Scholar
• Dessev G., Iovcheva-Dessev C., Bischoff J. R., Beach D., Goldman R. A complex containing p34cdc2 and cyclin B phosphorylates the nuclear lamin and disassembles nuclei of clam oocytes in vitro. J. Cell. Biol. 1991; 112(4)523–533
   PubMed Web of Science ®Google Scholar
• Doree M., Labbe J. C., Picard A. M phase-promoting factor: Its identification as the M phase-specific H1 histone kinase and its activation by dephosphorylation. J. Cell Sci. 1989; 12(Suppl.)39–51
   Google Scholar
• Kellogg D. R., Oegema K., Raff J., Schneider K., Alberts B. M. CP60: A microtubule-associated protein that is localized to the centrosome in a cell cycle-specific manner. Molec. Biol. Cell 1995; 6(12)1673–1684
   PubMed Web of Science ®Google Scholar
• Fellous A., Kubelka M., Thibier C., Taieb F., Haccard O., Jessus C. Association of p34cdc2 kinase and MAP kinase with microtubules during the meiotic maturation of Xenopus oocytes. Int. J. Dev. Biol. 1994; 38(4)651–659
   PubMed Web of Science ®Google Scholar
• Tombes R. M., Peloquin J. G., Borisy G. G. Specific association of an M-phase kinase with isolated mitotic spindles and identification of two of its substrates as MAP4 and MAP1B. Cell Regul. 1991; 2(11)861–874
   PubMedGoogle Scholar
• Hartwell L. H., Weinert T. A. Checkpoints: Controls that ensure the order of cell cycle events. Science 1989; 246: 629–634
   PubMed Web of Science ®Google Scholar
• Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992; 71: 543–546
   PubMed Web of Science ®Google Scholar
• Ozbun M. A., Butel J. S. Tumor suppressor p53 mutations and breast cancer: A critical analysis. Adv. Cancer Res. 1995; 66: 71–142
   PubMed Web of Science ®Google Scholar
• Burns T. F., El-Deiry W. S. The p53 pathway and apoptosis. J. Cell. Physiol. 1999; 181: 231–239
   PubMed Web of Science ®Google Scholar
• Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991; 51: 6304–6311
   PubMed Web of Science ®Google Scholar
• Graeber T. G., Peterson J. F., Tsai M., Monica K., Fornance A. J., Jr., Giaccia A. J. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Molec. Cell. Biol. 1994; 14: 6264–6277
   PubMed Web of Science ®Google Scholar
• Linke S. P., Clarkin K. C., Di Leonardo A., Tsou A., Wahl G. M. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 1996; 10: 934–947
   PubMed Web of Science ®Google Scholar
• Lowe S. W., Ruley H. E. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 1993; 7: 535–545
   PubMed Web of Science ®Google Scholar
• El-Deiry W. S., Kern S. E., Pietenpol J. A., Kinzler K. W., Vogelstein B. Definition of a consensus binding site for p53. Nature Genet. 1992; 1: 45–49
   PubMed Web of Science ®Google Scholar
• Kern S. E., Pietenpol J. A., Thiagalingam S., Seymour A., Kinzler K. W., Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 256: 827–830
   PubMed Web of Science ®Google Scholar
• Pietenpol J. A., Tokino T., El-Deiry W. S., Kinzler K. W., Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA 1994; 91: 1998–2002
   PubMed Web of Science ®Google Scholar
• Agarwal M. L., Taylor W. R., Chernov M. V., Chernova O. B., Stark G. R. The p53 network. J. Biol. Chem. 1999; 273: 1–4
   Web of Science ®Google Scholar
• Harvey M., Sands A. T., Weiss R. S., Hegi M. E., Wiseman R. W., Pantazis P., Giovanella B. C., Tainsky M. A., Bradley A., Donehower L. A. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 1993; 8: 2457–2467
   PubMed Web of Science ®Google Scholar
• Brugarolas J., Moberg K., Boyd S. D., Taya Y., Jacks T., Lees J. A. Inhibi- tion of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein- mediated G1 arrest after gamma-irradiation. Proc. Natl. Acad. Sci. USA 1999; 96: 1002–1007
   PubMed Web of Science ®Google Scholar
• Brugarolas J., Chandrasekaran C., Gordon J. I., Beach D., Jacks T., Hannon G. J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995; 377: 552–557
   PubMed Web of Science ®Google Scholar
• Deng C. X., Zhang P. M., Harper J. W., Elledge S. J., Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675–684
   PubMed Web of Science ®Google Scholar
• Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805–816
   PubMed Web of Science ®Google Scholar
• Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995; 9: 1149–1163
   PubMed Web of Science ®Google Scholar
• Xiong Y. Why are there so many CDK inhibitors?. Biochim. Biophys. Acta Rev. Cancer 1996; 1288: 1–5
   Google Scholar
• Sharpless N. E., Dephino R. A. The INK4A/ARF locus and its two gene products. Curr. Opin. Gen. Dev. 1999; 9: 22–30
   PubMed Web of Science ®Google Scholar
• Jin P., Gu Y., Morgan D. O. Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J. Cell Biol. 1996; 134: 963–970
   PubMedGoogle Scholar
• Rhind N., Furnari B., Russel P. Cdc2 tyrosine phosphorylation is required for the DNA damage checkpoint in fission yeast. Genes Dev. 1997; 511: 504–510
   Google Scholar
• Coleman T. R., Dunphy W. G. Cdc2 regulatory factors. Curr. Opin. Cell Biol. 1994; 6: 877–882
   PubMed Web of Science ®Google Scholar
• Peng C. Y., Graves P. R., Thoma R. S. A., Wu, Shaw A. S., Piwnica-Worms H. Mitotic and G2 checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997; 277: 1501–1505
   PubMed Web of Science ®Google Scholar
• Chen L., Liu T. H., Walworth N. C. Association of Chk1 with 14-3-3 proteins is stimulated by DNA damage. Genes Dev. 1999; 13: 675–685
   PubMed Web of Science ®Google Scholar
• Agarwal M. L., Agarwal A., Taylor W. R., Stark G. R. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA 1995; 92: 8493–8497
   PubMed Web of Science ®Google Scholar
• Innocente S. A., Abrahamson J. L. A., Cogswell J. P., Lee J. M. p53 regulates a G2 checkpoint through cyclin B1. Proc. Natl. Acad. Sci. USA 1999; 96: 2147–2152
   PubMed Web of Science ®Google Scholar
• Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J. P., Sedivy J. M., Kinzler K. W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497–1501
   PubMed Web of Science ®Google Scholar
• Chan T. A., Hermeking H., Lengauer C., Kinzler K. W., Vogelstein B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401: 616–620
   PubMed Web of Science ®Google Scholar
• Taylor W. R., DePrimo S. E., Agarwal A., Agarwal M. L., Schonthal A. H., Katula K. S., Stark G. R. Mechanisms of G2 arrest in response to overexpression of p53. Molec. Biol. Cell 1999; 10(11)3607–3622
   PubMed Web of Science ®Google Scholar
• Flatt P. M., Tang L. J., Scatena C. D., Stak S. T., Pientenpol J. A. p53 regulation of G2 checkpoint is retinoblastoma protein dependent. Mol. Cell Biol. 2000; 20(12)4210–4223
   PubMed Web of Science ®Google Scholar
• Toyoshima F., Moriguchi T., Wada A., Fukuda M., Nishida E. Nuclear export of cyclin B1 and its possible role in the DNA damage-induced G2 checkpoint. EMBO J. 1998; 17: 2728–2735
   PubMed Web of Science ®Google Scholar
• Li J., Meyer A. N., Donoghue D. J. Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation. Proc. Natl. Acad. Sci. USA 1997; 94: 502–507
   PubMed Web of Science ®Google Scholar
• Pines J., Hunter T. Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J. Cell Biol. 1991; 115: 1–17
   PubMed Web of Science ®Google Scholar
• Jin P., Hardy S., Morgan D. O. Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J. Cell Biol. 1998; 141: 875–885
   PubMed Web of Science ®Google Scholar
• Amon A. The spindle checkpoint. Curr. Opin. Genet. Dev. 1999; 9: 69–75
   PubMed Web of Science ®Google Scholar
• King R. W., Deshaies R. J., Peters J. M., Kirschner M. W. How proteolysis drives the cell cycle. Science 1996; 274: 1652–1659
   PubMed Web of Science ®Google Scholar
• Li X., Nicklas R. B. Mitotic forces control a cell-cycle checkpoint. Nature 1995; 373: 630–632
   PubMedGoogle Scholar
• Li X., Nicklas R. B. Tension-sensitive kinetochore phosphorylation and the chromosome distribution checkpoint in praying mantid spermatocytes. J. Cell. Sci. 1997; 110: 537–545
   PubMed Web of Science ®Google Scholar
• Waters J. C., Chen R. H., Murray A. W., Salmon E. D. Localization of Mad2 to kinetochores depends on microtubule attachment, not tension. J. Cell Biol. 1998; 141: 1181–1191
   PubMed Web of Science ®Google Scholar
• Kim S. H., Lin D. P., Matsumoto S., Kitazono A., Matsumoto T. Fission yeast Slp1: An effector of the Mad2-dependent spindle checkpoint. Science 1998; 279: 1045–1047
   PubMedGoogle Scholar
• Fang G. W., Yu H. T., Kirschner M. W. The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation. Genes Dev. 1998; 12: 1871–1883
   PubMedGoogle Scholar
• Kallio M., Weinstein J., Daum J. R., Burke D. J., Gorbsky G. J. Mammalian p55CDC mediates association of the spindle checkpoint protein Mad2 with the cyclosome/anaphase-promoting complex, and is involved in regulating anaphase onset and late mitotic events. J. Cell. Biol. 1998; 141: 1393–1406
   PubMedGoogle Scholar
• Li Y., Gorbea C., Mahaffey D., Rechsteiner M., Benezra R. MAD2 associates with the cyclosome/anaphase-promoting complex and inhibits its activity. Proc. Natl. Acad. Sci. USA 1997; 94: 12,431–12,436
   Google Scholar
• Chen R-H., Waters J. C., Salmon E. D., Murray A. W. Association of spindle assembly checkpoint component XMAD2 with unattached kinetochores. Science 1996; 274: 242–246
   PubMedGoogle Scholar
• Li Y., Benezra R. Identification of a human mitotic checkpoint gene, hsMAD2. Science 1996; 274: 246–248
   PubMed Web of Science ®Google Scholar
• Taylor S. S., McKeon F. Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. Cell 1997; 89: 727–735
   PubMed Web of Science ®Google Scholar
• Taylor S. S., Ha E., McKeon F. The human homologue of Bub3 is required for kinetochore localization of Bub1 and a Mad3/Bub1-related protein kinase. J. Cell Biol. 1998; 142: 1–11
   PubMed Web of Science ®Google Scholar
• Cahill D. P., Lengauer C., Yu J., Riggins G. J., Willson J. K. V., Markowitz S. D., Kinzler K. W., Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature 1998; 392: 300–303
   PubMed Web of Science ®Google Scholar
• Lanni J. S., Jacks T. S. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Molec. Cell. Biol. 1998; 18: 1055–1064
   PubMed Web of Science ®Google Scholar
• Khan S. H., Wahl G. M. p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res. 1998; 58: 396–401
   PubMedGoogle Scholar
• Stewart Z. A., Leach S. D., Pietenpol J. A. p21Waf1/Cip1 inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Molec. Cell. Biol. 1999; 19: 205–215
   PubMed Web of Science ®Google Scholar
• Sinov R. V., Haupt Y. The cellular response to p53: The decision between life and deth. Oncogene. 1999; 18: 6145–6157
   PubMed Web of Science ®Google Scholar
• Choisy-Rossi C., Reisdorf P., Yonish-Rouach E. Mechanisms of p53-induced apoptosis: In search of genes which are regulated during p53-mediated cell death. Toxicol. Lett. 1998; 103: 491–496
   Web of Science ®Google Scholar
• Yonish-Rouach E., Deguin V., Zaitchouk T., Breugnot C., Mishal Z., Jenkins J. R., May E. Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53. Oncogene 1996; 12: 2197–2205
   Google Scholar
• Attardi L. D., Lowe S. W., Brugarolas J., Jacks T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J. 1996; 15: 3693–3701
   PubMed Web of Science ®Google Scholar
• Sabbatini P., Lin J. Y., Levine A. J., White E. Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev. 1995; 9: 2184–2192
   PubMed Web of Science ®Google Scholar
• Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B. R., Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646–649
   PubMed Web of Science ®Google Scholar
• Owen-Schaub L. B., Zhang W., Cusack J. C., Angelo L. S., Santee S. M., Fujiwara T., Roth J. A., Deisseroth A. B., Zhang W.-W., Kruzel E., Radinsky R. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Molec. Cell. Biol. 1995; 15: 3032–3040
   PubMed Web of Science ®Google Scholar
• Ashkenazi A., Dixit V. M. Death receptors: Signaling and modulation. Science 1998; 281: 1305–1308
   PubMed Web of Science ®Google Scholar
• Green D., Kroemer G. The central executioners of apoptosis: Caspases or mitochondria?. Trends Cell. Biol. 1998; 8: 267–271
   PubMed Web of Science ®Google Scholar
• Friesen C., Herr I., Krammer P. H., Debatin K. M. Involvement of the CD95 (APO 1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med. 1996; 2: 574–577
   PubMed Web of Science ®Google Scholar
• Juin P., Hueber A. O., Littlewood T., Evan G. c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev. 1999; 13(11)1367–1381
   PubMed Web of Science ®Google Scholar
• Fuchs E. J., McKenna K. A., Bedi A. p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32β. Cancer Res. 1997; 57: 2550–2554
   PubMed Web of Science ®Google Scholar
• Wu G. S., Burns T. F., McDonald E. R., III, Jiang W., Meng R., Krantz I. D., Kao G., Gan D. D., Zhou J. Y., Muschel R., Hamilton S. R., Spinner N. B., Markowitz S., Wu G., El-Deiry W. S. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet 1997; 17: 141–143
   PubMed Web of Science ®Google Scholar
• Miyashita T., Reed J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293–299
   PubMed Web of Science ®Google Scholar
• Kelekar A., Thompson C. B. Bcl-2-family proteins: The role of the BH3 domain in apoptosis. Trends Cell Biol. 1998; 8: 324–330
   PubMed Web of Science ®Google Scholar
• Knudson C. M., Tung K. S. K., Tourtellotte W. G., Brown G. A. J., Korsmeyer S. J. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995; 270: 96–99
   PubMed Web of Science ®Google Scholar
• Brady H. J., Salomons G. S., Bobeldijk R. C., Berns A. J. T cells from baxalpha transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53 gene product. EMBO J. 1996; 15(6)1221–1230
   PubMed Web of Science ®Google Scholar
• Yin C., Knudson C. M., Korsmeyer S. J., Van D. T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385: 637–640
   PubMed Web of Science ®Google Scholar
• McCurrach M. E., Connor T. M., Knudson C. M., Korsmeyer S. J., Lowe S. W. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA 1994; 94: 2345–2349
   Google Scholar
• Johnson T. M., Yu Z. X., Ferrans V. J., Lowenstein R. A., Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA 1996; 93(21)11,848–11,852
   Google Scholar
• Li P. F., Dietz R., von Harsdorf R. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J. 1999; 18(21)6027–6036
   PubMed Web of Science ®Google Scholar
• Yin Y. X., Terauchi Y., Solomon G. G., Aizawa S., Rangarajan P. N., Yazaki Y., Kadowaki T., Barrett J. C. Involvement of p85 in p53-dependent apoptotic response to oxidative stress. Nature 1998; 391: 707–710
   PubMed Web of Science ®Google Scholar
• Polyak K., Xia Y., Zweier J. L., Kinzler K. W., Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 300–305
   PubMed Web of Science ®Google Scholar
• Venot C., Maratrat M., Dureuil C., Conseiller E., Bracco L., Debussche L. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 1998; 17: 4668–4679
   PubMed Web of Science ®Google Scholar
• Caelles C., Helmberg A., Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994; 370: 220–223
   PubMed Web of Science ®Google Scholar
• Bates S., Vousden K. H. Mechanisms of p53-mediated apoptosis. Cell. Molec. Life Sci. 1999; 55: 28–37
   PubMed Web of Science ®Google Scholar
• Chen X. B., Ko L. J., Jayaraman L., Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 1996; 10: 2438–2451
   PubMed Web of Science ®Google Scholar
• Haupt Y., Rowan S., Shaulian E., Vousden K. H., Oren M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 1995; 9: 2170–2183
   PubMed Web of Science ®Google Scholar
• Murphy M., Hinman A., Levine A. J. Wild-type p53 negatively regulates expression of a microtubule-associated protein. Genes Dev. 1996; 10: 2971–2980
   PubMed Web of Science ®Google Scholar
• Roperch J. P., Alvaro V., Prieur S., Tuynder M., Nemani M., Lethrosne F., Piouffre L., Gendron M. C., Israeli D., Dausset J., Oren M., Amson R., Telerman A. Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression. Nature Med. 1998; 4: 835–838
   PubMed Web of Science ®Google Scholar
• Prisco M., Hongo A., Rizzo M. G., Sacchi A., Baserga R. The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Molec. Cell. Biol. 1994; 17: 1084–1092
   Google Scholar
• Wang X. W., Yeh H., Schaeffer L., Roy R., Moncollin V., Egly J.-M., Wang Z., Friedberg E. C., Evans M. K., Taffe B. G., Bohr V. A., Weeda G., Hoeijmakers J. H. J., Forrester K., Harris C. C. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nature Genet. 1995; 10: 188–195
   PubMed Web of Science ®Google Scholar
• Bennett M., Macdonald K., Chan S. W., Luzio J. P., Simari R., Weissberg P. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis. Science 1998; 282: 290–293
   PubMed Web of Science ®Google Scholar
• Puisieux A., Lim S., Groopman J., Ozturk M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 1991; 51(22)6185–6189
   PubMed Web of Science ®Google Scholar
• Yang J., Deuksen-Hughes P. A new approach to identifying genotoxic carcinogens: p53 induction as an indicator of genotoxic damage. Carcinogenesis 1998; 19(6)1117–1125
   PubMed Web of Science ®Google Scholar
• Ramet M., Castren K., Jarvinen K., Pekkala K., Turpeenniemi-Hujanen T., Soini Y., Paakko P., Vahakangas K. p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines. Carcinogenesis 1995; 16(9)2117–2124
   PubMed Web of Science ®Google Scholar
• McGregor W. G. DNA repair, DNA replication, and UV mutagenesis. J. Invest. Dermatol. Symp. Proc. 1999; 4(1)1–5
   PubMed Web of Science ®Google Scholar
• Daya-Grosjean L., Dumaz N., Sarasin A. The specificity of p53 mutation spectra in sunlight induced human cancers. J. Photochem. Photobiol. B 1995; 28(2)115–124
   PubMed Web of Science ®Google Scholar
• Hussain S. P., Harris C. C. p53 mutation spectum and load: The generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat. Res. 1999; 428: 23–32
   PubMed Web of Science ®Google Scholar
• Wang J. S., Groopman J. D. DNA damage by mycotoxins. Mutat. Res. 1999; 424(1–2)167–181
   PubMed Web of Science ®Google Scholar
• Yao S. L., Akhtar A. J., McKenna K. A., Bedi G. C., Sidransky D., Mabry M., Ravi R., Collector M. I., Jones R. J., Sharkis S. J., Fuchs E. J., Bedi A. Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nature Med. 1996; 2: 1140–1143
   PubMed Web of Science ®Google Scholar
• Anon., Ironing out the angles in p53. Nature Struct. Biol. 1995; 2: 253–254
   PubMedGoogle Scholar
• Russell K. J., Wiens L. W., Demers W., Galloway D. A., Plon S. E., Groudine M. Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1-checkpoint competent cells. Cancer Res. 1995; 55: 1639–1642
   PubMed Web of Science ®Google Scholar
• Blume E. Researchers gain footholds in the cell cycle. J. Natl. Cancer Inst. 1995; 87: 1504–1505
   PubMed Web of Science ®Google Scholar
• Bunz F., Hwang P. M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K. W., Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 1999; 104: 263–269
   PubMed Web of Science ®Google Scholar
• Wang Q., Fan S., Eastman A., Worland P. J., Sausville E. A., O'Connor P. M. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 1996; 88: 956–965
   PubMed Web of Science ®Google Scholar
• Roberge M., Berlinck R. G. S., Xu L., Anderson H. J., Lim L. Y., Curman D., Stringer C. M., Friend S. H., Davies P., Vincent I., Haggarty ., Kelly M. T., Britton R., Piers E., Andersen R. J. High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. Cancer Res. 1998; 58: 5701–5706
   PubMedGoogle Scholar